Clinical efficacy and safety study of the combination of vonoprazan and amoxicillin in the treatment of first-time patients with Helicobacter pylori infection
Clinical efficacy and safety study of the combination of vonoprazan and amoxicillin in the treatment of first-time patients with Helicobacter pylori infection
Objective To study the clinical efficacy and safety of vororacin combined with amoxicillin in patients receiving first treatment of H.pylori(Helicobacter pylori,Hp)infection.Methods A total of 100 Hp infected patients first treated at Beijing Luhe Hospital affiliated to Capital Medical University from March 2022 to February 2023 were selected and divided into control group(n=44)and study group(n=56).Patients in the control group received a quadruple treatment plan(rabeprazole+Colloidal Bismuth Pectin+amoxicillin+clarithromycin),while patients in the study group received a dual treatment plan(vonoprazan+amoxicillin).Treatment efficacy,time to symptom relief and adverse effects were compared between the two groups.Results The Hp eradication rate in the study group was significantly higher than the control group(94.64％vs.81.82％,P＜0.05),and the Hp recurrence rate 1 month after treatment in the study group was significantly lower than that in the control group(3.77％vs.22.22％,P＜0.05);The duration of pain relief and other gastrointestinal symptoms in the study group were lower than those in the control group(P＜0.05);The incidence of adverse reactions during the treatment period was significantly lower than that in the control group(7.14％vs.22.73％,P＜0.05).Conclusion The combination therapy of Vonoprazan and Amoxicillin has a high eradication rate of Hp infection in the first treatment,a low incidence of adverse reactions during treatment,and a low recurrence rate of Hp after treatment.
维普
万方数据